Literature DB >> 19641361

Long-term clinical outcome of diagnostic transurethral resection of the prostate in patients with elevated prostate-specific antigen level and minor lower urinary tract symptoms.

Koenraad van Renterghem1, Gommert van Koeveringe, Ruth Achten, Philip van Kerrebroeck.   

Abstract

INTRODUCTION: In patients with minor lower urinary tract symptoms (LUTS), elevated prostate-specific antigen (PSA) levels and (multiple) negative multi-site biopsies, therapy decision is complex. Long-term outcome of a diagnostic transurethral resection of the prostate (TURP) in these patients needs to be determined.
METHODS: We retrospectively evaluated patients with minor LUTS, elevated PSA levels (>or=4 ng/ml) and no signs of prostate cancer. Patients with bladder outlet obstruction (BOO) underwent TURP. When TURP showed no malignancy, patients were annually evaluated by PSA testing and the International Prostate Symptom Score (IPSS).
RESULTS: The study included 82 consecutive patients satisfying the inclusion criteria. All patients underwent TURP. No malignancy was encountered in 74 patients (90.2%). Of this group, 36 patients were followed >3 years (mean 62.1 months). One patient (2.8%) showed a persistently rising PSA level with positive extended multi-site biopsies 4 years after TURP, implying further treatment. 35 patients (97.2%) had a permanent complete normalization of PSA levels (<4 ng/ml) together with normalized IPSS.
CONCLUSIONS: We consider an elevated PSA level in patients with minor LUTS and (multiple) negative multi-site biopsies as a sign of BOO. If these patients receive a diagnostic TURP, long-term outcome is excellent. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19641361     DOI: 10.1159/000224870

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  4 in total

1.  A new model consists of intravesical prostatic protrusion, prostate volume and serum prostatic-specific antigen in the evaluation of prostate cancer.

Authors:  Ding Xu; Yongjiang Yu; Yunkai Zhu; Tao Huang; Yaqing Chen; Jun Qi
Journal:  Pathol Oncol Res       Date:  2013-11-01       Impact factor: 3.201

2.  Benign prostatic hyperplasia: from bench to clinic.

Authors:  Tag Keun Yoo; Hee Ju Cho
Journal:  Korean J Urol       Date:  2012-03-19

3.  The role of transurethral resection of the prostate for patients with an elevated prostate-specific antigen.

Authors:  Hee Ju Cho; Soon Cheol Shin; Jeong Man Cho; Jung Yoon Kang; Tag Keun Yoo
Journal:  Prostate Int       Date:  2014-12-30

Review 4.  A new algorithm in patients with elevated and/or rising prostate-specific antigen level, minor lower urinary tract symptoms, and negative multisite prostate biopsies.

Authors:  Koenraad van Renterghem; Gommert Van Koeveringe; Ruth Achten; Philip van Kerrebroeck
Journal:  Int Urol Nephrol       Date:  2009-06-03       Impact factor: 2.370

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.